Evidence map›Paper›PMID 38504977›Full record

ArticleFrontiers in immunology2024

T cell specific deletion of Casitas B lineage lymphoma-b reduces atherosclerosis, but increases plaque T cell infiltration and systemic T cell activation.

Winnie G Vos, Bram W van Os, Myrthe den Toom, Linda Beckers, Cindy P A A van Roomen, Claudia M van Tiel, Bhopal C Mohapatra, Hamid Band, Katrin Nitz, Christian Weber and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Targeted drug delivery systems for atherosclerosis.Journal of nanobiotechnology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Winnie G VosDepartment of Medical Biochemistry, Amsterdam University Medical Centers (UMC) Location University of Amsterdam, Amsterdam, Netherlands.
Bram W van OsDepartment of Medical Biochemistry, Amsterdam University Medical Centers (UMC) Location University of Amsterdam, Amsterdam, Netherlands.
Myrthe den ToomDepartment of Medical Biochemistry, Amsterdam University Medical Centers (UMC) Location University of Amsterdam, Amsterdam, Netherlands.
Linda BeckersDepartment of Medical Biochemistry, Amsterdam University Medical Centers (UMC) Location University of Amsterdam, Amsterdam, Netherlands.
Cindy P A A van RoomenDepartment of Medical Biochemistry, Amsterdam University Medical Centers (UMC) Location University of Amsterdam, Amsterdam, Netherlands.
Claudia M van TielDepartment of Medical Biochemistry, Amsterdam University Medical Centers (UMC) Location University of Amsterdam, Amsterdam, Netherlands.
Bhopal C MohapatraDepartment of Genetics, Cell Biology and Anatomy, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Hamid BandEppley Institute for Research in Cancer and Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, United States.
Katrin NitzInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Christian WeberInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Dorothee AtzlerInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Menno P J de WintherDepartment of Medical Biochemistry, Amsterdam University Medical Centers (UMC) Location University of Amsterdam, Amsterdam, Netherlands.
Laura A BosmansDepartment of Medical Biochemistry, Amsterdam University Medical Centers (UMC) Location University of Amsterdam, Amsterdam, Netherlands.
Esther LutgensInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Tom T P SeijkensDepartment of Medical Biochemistry, Amsterdam University Medical Centers (UMC) Location University of Amsterdam, Amsterdam, Netherlands.
Institute of Infection and Immunity · CAUniversity of Amsterdam · NLAmsterdam University Medical Centers · NLGerman Centre for Cardiovascular Research · DEMaastricht University · NLMayo Clinic in Arizona · USNebraska Medical Center · USUniversity of Nebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Atherosclerosis is a lipid-driven inflammatory disease of the arterial wall, and the underlying cause of the majority of cardiovascular diseases. Recent advances in high-parametric immunophenotyping of immune cells indicate that T cells constitute the major leukocyte population in the atherosclerotic plaque. The E3 ubiquitin ligase Casitas B-lymphoma proto-oncogene-B (CBL-B) is a critical intracellular regulator that sets the threshold for T cell activation, making CBL-B a potential therapeutic target to modulate inflammation in atherosclerosis. We previously demonstrated that complete knock-out of CBL-B aggravated atherosclerosis in Methods: To further study the T cell specific role of CBL-B in atherosclerosis, Results: Cbl-b Conclusion: In conclusion, Cbl-b

Indexed as

AtherosclerosisLymphomaPlaque, AtheroscleroticAdaptor Proteins, Signal TransducingAnimalsApolipoproteins ECD8-Positive T-LymphocytesMiceMice, KnockoutProto-Oncogene Proteins c-cblAdaptor Proteins, Signal TransducingApolipoproteins ECblb protein, mouseProto-Oncogene Proteins c-cblatherosclerosisCBL-BexhaustioninflammationT cells

Identifiers

PMID38504977
PMCPMC10949527
OpenAlexW4392372027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.